Clinical Trials
20 trialsNCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT06682728 2026-04-30
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
University of California, Irvine
Phase 2 Recruiting
NCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04953104 2026-04-15
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02845323 2026-04-06
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04637594 2026-03-20
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04848519 2026-02-19
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
Phase 2 Active not recruiting
NCT04863885 2025-12-17
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT03387761 2025-03-05
NABUCCO
The Netherlands Cancer Institute
Phase 1 Completed
NCT04871594 2025-03-05
TURANDOT
The Netherlands Cancer Institute
Phase 1 Completed
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT05200988 2024-03-18
Indi-Blade
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT03758781 2023-04-14
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT03115801 2021-09-22
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03106610 2018-05-24
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
M.D. Anderson Cancer Center
Phase 1 Terminated